Comparison of Electroconvulsive Therapy and Magnetic Seizure Therapy for Major Depressive Disorder in Patients Aged 12 to 80
Led by The Second Hospital of Anhui Medical University · Updated on 2026-07-17
200
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing the effects and tolerability of Electroconvulsive Therapy ECT and Magnetic Seizure Therapy MST in treating patients with major depressive disorder MDD. The study focuses on evaluating these two neuromodulation therapies when added to standard medication, aiming to better understand their impact on depression symptoms and cognitive function.
Participants receive either active Electroconvulsive Therapy or Magnetic Seizure Therapy two to four times per week following a standardized protocol. Treatment is tailored individually regarding intensity, location, session number, and duration to ensure safety and targeting. Each participant will continue therapy until they meet specific response criteria or complete up to 10 sessions.
During the study, participants depression and anxiety levels will be assessed regularly using established rating scales at baseline, after each treatment session, and six months post-treatment. Cognitive function and brain activity will also be evaluated before and after the treatment period, which averages about two weeks. Heart rate variability will be monitored as an additional physiological measure. Participants will be closely observed throughout the intervention and follow-up phases to gather comprehensive data on treatment effects.
CONDITIONS
Brief Title
Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure Therapy
Research Team
Y
Yanghua Tian PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of major depressive disorder confirmed by two psychiatrists using DSM-5 criteria
Stable medication regimen before enrollment
Indicated for neuromodulation treatment or having visual field defects
You will not qualify if you...
Presence of major systemic diseases
Received neuromodulation treatment within the past 3 months
Pregnancy or potential pregnancy
Presence of metal implants or claustrophobia
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Treatment
Duration - About 2 weeks
Participants receive either Electroconvulsive Therapy or Magnetic Seizure Therapy two to four times a week alongside their standard medication until they meet response criteria or complete up to 10 sessions.
Multiple treatment sessions per week
Follow-up
Duration - 6 months
Participants are monitored with assessments of depression, anxiety, cognitive function, heart rate variability, and brain activity at the end of treatment and up to six months after intervention ends.
Regular follow-up visits during this period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Trial of 40 Hz Light Neurostimulation Therapy to Treat Major Depressive Disorder
Evaluating 5-hydroxytryptophan and Creatine Supplements to Enhance Antidepressant Treatment in Adults with Major Depressive Disorder Using Brain Imaging and Serotonin Measures
Randomized Study Evaluating a Single Oral Dose of CYB003 to Understand Brain and Symptom Changes in Adults With Major Depressive Disorder and Anxiety
Phase 2 Study on the Safety and Effectiveness of Zelquistinel Compared to Placebo for Treating Major Depressive Disorder in Adults Aged 18 to 64
Evaluating Oral DT120 Compared to Placebo in Adults With Major Depressive Disorder
A 12-Week Double-Blind Study Followed by a 40-Week Open-Label Extension
Psilocybin and Brain Activity Changes in Adults With Depression A Randomized Neuroimaging Study
Evaluating Vortioxetine for Major Depressive Disorder in Japanese Teens Aged 12 to 17 Using Daily Oral Tablets Compared to Placebo
Phase 2 Study of Oral Icalcaprant for Treating Major Depressive Disorder in Adults Aged 18 to 65
Evaluating Valbenazine for Adults With Tardive Dyskinesia Experiencing Symptoms During or After VMAT2 Inhibitor Treatment
Randomized Study Comparing AXS-05 and Bupropion for Preventing Relapse in Major Depressive Disorder
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Changes in Cerebral Hemodynamic Among Patients With Schizophrenia or Bipolar Disorder Receiving Electroconvulsive Therapy: A Task-Related Functional Near-Infrared Spectroscopy Study.
Cognitive preservation advantage and efficacy balance of magnetic seizure therapy in adolescent Major Depressive Disorder: a randomized controlled trial revealing efficacy cognition decoupling phenomenon.
Frontal and temporal cortical functional recovery after electroconvulsive therapy for depression: A longitudinal functional near-infrared spectroscopy study.
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.